NEW YORK, August 14, 2017 /PRNewswire/ --
If you want a Stock Review on HZNP, MYL, NBIX, or RIGL then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. The top fifty Generic Drugs producers had combined revenues of $92 billion in 2016, according to a Visiongain report. The top ten generic-drug producers have a 62% share of the total revenue made by these top fifty companies. Additionally, 30% of the top fifty generic-drug producers fall under the rest-of-the-world region. In today's pre-market research, DailyStockTracker.com highlights the performances of Horizon Pharma PLC (NASDAQ: HZNP), Mylan N.V. (NASDAQ: MYL), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Daily Stock Tracker published free research reports on these stocks today at:
Dublin, Ireland headquartered Horizon Pharma PLC's stock jumped 4.68%, finishing last Friday's trading session at $12.08. A total volume of 5.29 million shares was traded, which was above their three months average volume of 4.55 million shares. The Company's shares have gained 18.55% over the previous three months. The stock is trading above its 50-day moving average by 0.92%. Additionally, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases, have a Relative Strength Index (RSI) of 48.06.
On August 03rd, 2017, Horizon Pharma announced that it has appointed Pascale Witz and James Shannon, M.D. to its Board of Directors. Ms. Witz brings more than two decades of global healthcare management experience to the Board, and most recently served as Executive Vice President, global diabetes and cardiovascular at Sanofi. Dr. Shannon brings more than 25 years of clinical development experience, and most recently served as The Chief Medical Officer of GlaxoSmithKline. See our free and comprehensive research report on HZNP at:
Shares in Hatfield, the UK-based Mylan N.V. ended at $30.88, dropping 4.37% from the last trading session. The stock recorded a trading volume of 11.08 million shares, which was above its three months average volume of 5.93 million shares. The Company's shares are trading 18.36% below their 50-day moving average. Moreover, shares of Mylan have an RSI of 21.42.
On August 07th, 2017, research firm Morgan Stanley reiterated its 'Equal-Weight' rating on the Company's stock with a decrease of the target price from $52 a share to $36 a share.
On August 08th, 2017, Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan, has received marketing authorization from the Drug Controller General of India for its antiretroviral drug Avonza™ (TLE400). Avonza™ is a fixed-dose combination comprised of Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg, recommended by the World Health Organization as an alternative first-line regimen for people being treated for HIV/AIDS. MYL free research report is just a click away at:
On Friday, shares in San Diego, California headquartered Neurocrine Biosciences Inc. recorded a trading volume of 705,126 shares. The stock rose 0.41%, closing the day at $54.07. The Company's shares have gained 14.43% in the last one month, 0.82% over the previous three months, and 39.72% on an YTD basis. The stock is trading 14.44% above its 50-day moving average and 17.62% above its 200-day moving average. Additionally, shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders, have an RSI of 70.49.
On July 21st, 2017, Neurocrine Biosciences announced that Julie Cooke is joining as Chief People Officer in September 2017, and will be a member of the Management Committee. Ms. Cooke comes to the Company from the Sanford Burnham Prebys Medical Research Institute, where she served as Senior Vice President for Human Resources and was a member of the executive management team. Sign up for your complimentary report on NBIX at:
At the close of trading on Friday, shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. recorded a trading volume of 445,151 shares. The stock finished the session 0.46% lower at $2.18. The Company's shares are trading below their 50-day moving average by 14.01%. Furthermore, shares of Rigel Pharma, which engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 30.85.
On August 01st, 2017, Rigel Pharmaceuticals reported financial results for Q2 and six months ended June 30th, 2017. For Q2 2017, net loss was $19.1 million, or $0.16 per basic and diluted share. For the six months ended June 30th, 2017, net loss was $34.5 million, or $0.29 per basic and diluted share. As of June 30th, 2017, the Company had cash, cash equivalents, and short-term investments of $82.3 million. Register for free on DailyStockTracker.com and download the latest research report on RIGL at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA